Page 1886 - Hematology_ Basic Principles and Practice ( PDFDrive )

1668.e10 Part X Transplantation

412. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for 432. Petersdorf EW, Kollman C, Hurley CK, et al: Effect of HLA class II
sustained remissions in leukemia. N Engl J Med 371(16):1507–1517, gene disparity on clinical outcome in unrelated donor hematopoietic
2014. cell transplantation for chronic myeloid leukemia: the US National
413. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing Marrow Donor Program Experience. Blood 98:2922, 2001.
+
CD19 chimeric antigen receptors for acute lymphoblastic leukaemia 433. Dodi IA, Van Rhee F, Forde HC, et al: CD4( ) bias in T cells cloned
in children and young adults: a phase 1 dose-escalation trial. Lancet from a CML patient with active graft versus leukemia effect. Cytotherapy
385(9967):517–528, 2015. 4:353, 2002.
414. Lee DW, Gardner R, Porter DL, et al: Current concepts in the diagnosis 434. Madrigal JA, Travers PJ, Dodi IA: Immunotherapeutic aspects of stem
and management of cytokine release syndrome. Blood 124(2):188–195, cell transplantation. Hematology 10:289, 2005.
+
+
2014. 435. Edinger M, Hoffmann P, Ermann J, et al: CD4 CD25 regulatory T
415. Ferrara JL, Reddy P: Pathophysiology of graft-versus-host disease. cells preserve graft-versus-tumor activity while inhibiting graft-versus-
Semin Hematol 43:3, 2006. host disease after bone marrow transplantation. Nat Med 9:1144, 2003.
416. Slavin S, Morecki S, Weiss L, et al: Nonmyeloablative stem cell trans- 436. Jones SC, Murphy GF, Korngold R: Post-hematopoietic cell transplan-
plantation: reduced-intensity conditioning for cancer immunotherapy— tation control of graft-versus-host disease by donor CD425 T cells to
from bench to patient bedside. Semin Oncol 31:4, 2004. allow an effective graft-versus-leukemia response. Biol Blood Marrow
417. Mapara MY, Kim YM, Wang SP, et al: Donor lymphocyte infusions Transplant 9:243, 2003.
mediate superior graft-versus-leukemia effects in mixed compared to 437. Hill GR, Teshima T, Gerbitz A, et al: Differential roles of IL-1 and
fully allogeneic chimeras: a critical role for host antigen-presenting cells. TNF-alpha on graft-versus-host disease and graft versus leukemia. J
Blood 100:1903, 2002. Clin Invest 104:459, 1999.
418. Mapara MY, Sykes M: Tolerance and cancer: mechanisms of tumor 438. Schmaltz C, Alpdogan O, Muriglan SJ, et al: Donor T cell-derived
evasion and strategies for breaking tolerance. J Clin Oncol 22:1136, TNF is required for graft-versus-host disease and graft-versus-tumor
2004. activity after bone marrow transplantation. Blood 101:2440, 2003.
419. Chakraverty R, Cote D, Buchli J, et al: An inflammatory checkpoint 439. Korngold R, Marini JC, De Baca ME, et al: Role of tumor necrosis
regulates recruitment of graft-versus-host reactive T cells to peripheral factor-alpha in graft-versus-host disease and graft-versus-leukemia
tissues. J Exp Med 203:2021, 2006. responses. Biol Blood Marrow Transplant 9:292, 2003.
420. Gattinoni L, Klebanoff CA, Palmer DC, et al: Acquisition of full effec- 440. Hsieh MH, Korngold R: Differential use of FasL- and perforin-mediated
tor function in vitro paradoxically impairs the in vivo antitumor efficacy cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid
+
of adoptively transferred CD8 T cells. J Clin Invest 115:1616, 2005. leukemia responses. Blood 96:1047, 2000.
421. Gattinoni L, Finkelstein SE, Klebanoff CA, et al: Removal of homeo- 441. Hsieh MH, Patterson AE, Korngold R: T-cell subsets mediate graft-
static cytokine sinks by lymphodepletion enhances the efficacy of versus-myeloid leukemia responses via different cytotoxic mechanisms.
+
adoptively transferred tumor-specific CD8 T cells. J Exp Med 202:907, Biol Blood Marrow Transplant 6:231, 2000.
2005. 442. Nebbioso A, Clarke N, Voltz E, et al: Tumor-selective action of HDAC
422. Wrzesinski C, Paulos CM, Gattinoni L, et al: Hematopoietic stem inhibitors involves TRAIL induction in acute myeloid leukemia cells.
cells promote the expansion and function of adoptively transferred Nat Med 11:77, 2005.
antitumor CD8 T cells. J Clin Invest 117:492, 2007. 443. Insinga A, Monestiroli S, Ronzoni S, et al: Inhibitors of histone
+
423. Chakraverty R, Eom HS, Sachs J, et al: Host MHC Class II antigen- deacetylases induce tumor-selective apoptosis through activation of the
presenting cells and CD4 cells are required for CD8-mediated graft- death receptor pathway. Nat Med 11:71, 2005.
versus-leukemia responses following delayed donor leukocyte infusions. 444. Reddy P, Maeda Y, Hotary K, et al: Histone deacetylase inhibitor
Blood 2006. suberoylanilide hydroxamic acid reduces acute graft-versus-host disease
424. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA
immunosurveillance and immunoediting. Immunity 21:137, 2004. 101:3921, 2004.
425. Boyer MW, Vallera DA, Taylor PA, et al: The role of B7 costimulation 445. Suntharalingam G, Perry MR, Ward S, et al: Cytokine storm in a phase
by murine acute myeloid leukemia in the generation and function of a 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med
+
CD8 T-cell line with potent in vivo graft-versus-leukemia properties. 355(10):1018–1028, 2006.
Blood 89:3477, 1997. 446. Page DB, Postow MA, Callahan MK, et al: Immune modulation in
426. Kolb HJ, Schmid C, Barrett AJ, et al: Graft-versus-leukemia reactions cancer with antibodies. Annu Rev Med 65:185–202, 2014.
in allogeneic chimeras. Blood 103:767, 2004. 447. Davila ML, Riviere I, Wang X, et al: Efficacy and toxicity management
427. Toubai T, Guoqing H, Rossi C, et al: Ikaros deficiency in host hemato- of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
poietic cells separates GVL from GVHD after experimental allogeneic Sci Transl Med 6(224):224ra25, 2014.
hematopoietic cell transplantation. Oncoimmunology 4(7):e1016699, 448. Teachey DT, Rheingold SR, Maude SL, et al: Cytokine release syn-
2015. drome after blinatumomab treatment related to abnormal macrophage
428. Toubai T, Mathewson N, Reddy P: The role of dendritic cells in graft- activation and ameliorated with cytokine-directed therapy. Blood
versus-tumor effect. Front Immunol 5:66, 2014. 121(26):5154–5157, 2013.
429. Blazar BR, Taylor PA, Boyer MW, et al: CD28/B7 interactions are 449. Kalos M, Levine BL, Porter DL, et al: T cells with chimeric antigen
required for sustaining the graft-versus-leukemia effect of delayed post- receptors have potent antitumor effects and can establish memory in
bone marrow transplantation splenocyte infusion in murine recipients patients with advanced leukemia. Sci Transl Med 3(95):95ra73, 2011.
of myeloid or lymphoid leukemia cells. J Immunol 159:3460, 1997. 450. Morgan RA, Yang JC, Kitano M, et al: Case report of a serious adverse
430. Porter DL, Antin JH: Donor leukocyte infusions in myeloid malignan- event following the administration of T cells transduced with a chi-
cies: new strategies. Best Pract Res Clin Haematol 19:737, 2006. meric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851,
+
431. Jiang YZ, Mavroudis D, Dermime S, et al: Alloreactive CD4 T 2010.
lymphocytes can exert cytotoxicity to chronic myeloid leukemia cells 451. Long AH, Haso WM, Shern JF, et al: 4-1BB costimulation ameliorates
processing and presenting exogenous antigen. Br J Haematol 93:606, T cell exhaustion induced by tonic signaling of chimeric antigen recep-
1996. tors. Nat Med 21(6):581–590, 2015.